Clinical and liver biopsy features of liver biopsy group (n=46)
| Patient features | Non-established PBC (n=22) | Overlap: Paris (n=12) | PBC (n=12) | Fisher’s exact P*†‡ |
| Age, mean (median, range) | 52 (54, 25–76) | 50 (55, 14–752) | 48 (50, 27–64) | 0.717§ |
| Sex: female | 18 (81.8%) | 10 (83.3%) | 12 (100%) | 0.389 |
| Substance abuse | 9 (40.9%) | 1 (8.3%) | 2 (16.7%) | 0.103 |
| Alcohol use | 9 (40.9%) | 3 (25.0%) | 1 (8.3%) | 0.121 |
| Overweight/obese | 20 (90.9%) | 9 (75.0%) | 10 (83.3%) | 0.435 |
| DM¶ | 5 (23.8%) | 1 (8.3%) | 5 (41.7%) | 0.175 |
| Biopsy | ||||
| BDI | 0 | 12 (100%) | 12 (100%) | <0.001*‡ |
| Fatty change | 12 (54.5%) | 2 (16.7%) | 5 (41.7%) | 0.110 |
| Fibrosis | 9 (64.3%) | 4 (66.7%) | 5 (50.0%) | 0.728 |
| Cirrhosis | 8 (61.5%) | 6 (75.0%) | 2 (25.6%) | 0.176 |
| Cholestasis | 1 (4.5%) | 5 (41.7%) | 2 (16.7%) | 0.016* |
| NASH | 8 (36.4%) | 2 (16.7%) | 3 (25.0%) | 0.586 |
| Piece meal necrosis | 4 (18.2%) | 11 (91.7%) | 1 (8.3%) | <0.001*† |
| Imaging | ||||
| Ascites¶ | 3 (13.6%) | 4/11 (36.4) | 0/11 (0%) | 0.068 |
| Varices¶ | 4/21 (19.05) | 4 (33.35) | 1/10 (10%) | 0.449 |
| Steatosis¶ | 7/20 (35.0%) | 3/9 (33.3%) | 4/11 (36.4%) | >0.999 |
| Serologies | ||||
| Hepatitis C | 8 (36.4%) | 0 | 0 | – |
| Hepatitis B | 1 (4.5%) | 0 | 0 | – |
| ANA | 2 (9.5%) | 8 (72.7%) | 4 (36.4%) | 0.001*†‡ |
| F-actin | 5 (26.3%) | 9 (75%) | 4 (33.3%) | 0.025* |
*Fisher’s exact text significant for non-established PBC versus overlap.
†Fisher’s exact test significant for overlap versus PBC-Paris.
‡Fisher’s exact test significant for non-established PBC versus PBC-Paris.
§Independent samples median test comparing age across three groups.
¶n less than the n presented at the header.
ANA, antinuclear antibody; BDI, bile duct injury; DM, diabetes mellitus; PBC, primary biliary cholangitis.